Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05285839 · ClinicalTrials.gov registry record · Phase 4

Dupixent and Narrowband UVB for Atopic Dermatitis

A Phase 4 study of Atopic Dermatitis, sponsored by Psoriasis Treatment Center of Central New Jersey.

Recruiting
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT05285839: Recruiting Phase 4 study of Atopic Dermatitis, sponsored by Psoriasis Treatment Center of Central New Jersey.

NCT05285839 is a Phase 4 study of Atopic Dermatitis that is actively recruiting participants, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 40 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05285839, a Phase 4 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Psoriasis Treatment Center of Central New Jersey.

RECRUITING
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Primary Outcome

Proportion of subjects achieving an IGA score of 0 or 1 with at least a 2 grade improvement at week 12

Conditions Studied

Atopic Dermatitis

Interventions

  • DRUG Dupixent

Study Locations (1)

New Jersey

  • Eczema Treatment Center of New Jersey - East Windsor

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-04-19
Est. Completion 2024-12-15
Phase Phase 4
Psoriasis Treatment Center of Central New Jersey

16 total trials

What NCT05285839 shows while recruiting

NCT05285839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Dupixent is the first listed.

NCT05285839 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT05285839 about?

NCT05285839 is a clinical study titled "Dupixent and Narrowband UVB for Atopic Dermatitis". 24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

What is the current status of trial NCT05285839?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2022-04-19. Estimated completion is 2024-12-15.

What conditions does trial NCT05285839 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT05285839?

The interventions under investigation include: Dupixent (DRUG).

Who is sponsoring clinical trial NCT05285839?

This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05285839 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05285839's enrollment target sits among peer trials

40 114th of 150 higher than 36 of 150 other Atopic Dermatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05285839

Source: ClinicalTrials.gov NCT05285839, the US trial registry maintained by the National Library of Medicine. NCT05285839 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.